News

HPV SELFY: THE FIRST FULL GENOTYPING HPV TEST VALIDATED FOR PRIMARY CERVICAL CANCER SCREENING ON SELF-COLLECTED SAMPLES
HPV SELFY: THE FIRST FULL GENOTYPING HPV TEST VALIDATED FOR PRIMARY CERVICAL CANCER SCREENING ON SELF-COLLECTED SAMPLES

Ulisse BioMed is proud to announce an important milestone reached: the validation of HPV Selfy as a primary cervical cancer...

NEW SCIENTIFIC PUBLICATION IN SUPPORT OF A TECHNOLOGY PATENTED BY ULISSE BIOMED
NEW SCIENTIFIC PUBLICATION IN SUPPORT OF A TECHNOLOGY PATENTED BY ULISSE BIOMED

While the world continues fighting against COVID-19 pandemic, still SARS- CoV-2 virus and its variants evolution raises great...

ULISSE BIOMED PARTICIPATES IN EUROGIN 2022
ULISSE BIOMED PARTICIPATES IN EUROGIN 2022

Ulisse BioMed participated in EUROGIN 2022 (European Research Organization on Genital Infection and Neoplasia), which was held...

POR FESR 2.3.b.1.bis
POR FESR 2.3.b.1.bis

Nel corso del 2017 l’azienda ha vissuto un momento di espansione in relazione all’allestimento della propria unità...

COMMUNICATION OF CONCESSION POR FESR 2.3.b.1
COMMUNICATION OF CONCESSION POR FESR 2.3.b.1

Ulisse BioMed was awarded a grant of € 5.011,92 in respect of the call for the Regional Operational Plan of the European...

1 2 3